Remdesivir for COVID‐19 pneumonia in patients with severe chronic kidney disease: A Case series and review of the literature
Ahmad Al Bishawi, Hamad Abdel Hadi, Eman Elmekaty and 5 more
Clinical Case Reports · 2022
doi:10.1002/ccr3.5467 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Abstract Remdesivir was the first antiviral agent to receive FDA authorization for severe COVID‐19 management, which restricts its use with severe renal impairment due to concerns that active metabolites might accumulate, causing renal toxicities. With limited treatment options, available evidence on such patient groups is important to assess for future safety.
Abstract licence: CC BY-NC
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.